24×7 Emergency Care

1-8-31/1, Minister Road, Secunderabad, Telangana 500003

EMERGENCY:Rapidly worsening memory and thinking over weeks — not months or years — with jerking movements, visual problems, or unsteadiness —call040-46324365immediately — 24 hours, 7 days— 24/7

NEUROINFECTIOUS DISORDERS & COMPLICATIONS

Prion Diseases and CJD in Hyderabad: Rapidly Progressive Dementia Demands Urgent Expert Assessment — Treatable Causes Must Be Excluded First

Q: My mother has become severely confused over the past 6 weeks, with jerking movements. The doctor says it might be CJD. Is there any treatment?

There is currently no treatment that can halt or reverse CJD. This is one of the most difficult things to communicate, and we do so at KIMS with the care it deserves. However, the most important first step is to confirm that the diagnosis is actually CJD — because several conditions that can look exactly like CJD in the early weeks are treatable and can be reversed. These include autoimmune encephalitis (particularly anti-NMDAR, anti-LGI1, and other antibody-mediated encephalitides), Hashimoto encephalopathy, paraneoplastic encephalopathy from an occult cancer, and severe metabolic disturbance. At KIMS, a comprehensive workup specifically tests for all these treatable causes before CJD is accepted as the diagnosis. If CJD is confirmed, the focus shifts entirely to keeping your mother comfortable, managing symptoms like the jerking movements and distress, and supporting your family through this. Please call 040-44885000.

Q: How is CJD diagnosed? Will a brain biopsy be needed?

Brain biopsy is not the standard diagnostic approach for CJD and is rarely performed. The diagnosis is made at KIMS through a combination of: MRI brain — specifically the DWI sequence showing the characteristic cortical ribboning pattern (high signal along the brain surface), which is present in approximately 90–95% of sporadic CJD; EEG — showing periodic sharp wave complexes in approximately 60–70% of cases; CSF analysis including 14-3-3 protein and RT-QuIC (the most specific test for prion disease). Together, these investigations provide a confident clinical diagnosis in most cases without biopsy. Brain biopsy is reserved for atypical cases where other diagnoses (treatable ones) have not been excluded and tissue diagnosis is essential for management decisions. Please call 040-44885000.

Q: My brother died of CJD 3 years ago. Should I be worried that I might get it?

The answer depends on the type of CJD your brother had. Sporadic CJD (the most common form, approximately 85% of cases) is not inherited and does not run in families. If your brother had sporadic CJD, your personal risk is no higher than the general population (approximately 1–2 per million per year). Variant CJD is not directly transmitted between family members — it comes from a dietary exposure (BSE-contaminated beef), not from your brother. Familial (genetic) CJD is autosomal dominant — if your brother had a PRNP gene mutation, each first-degree relative has a 50% chance of inheriting the mutation. If your brother's CJD was genetic, KIMS can arrange PRNP gene testing for you with full genetic counselling before and after the result. This is an important conversation that deserves specialist support. Please call 040-44885000.

Q: Can CJD be caught from medical procedures or from another person with CJD?

Iatrogenic CJD (from medical procedures) is documented but extremely rare, and has been associated with specific historical procedures now discontinued: cadaveric dura mater grafts (used in neurosurgery before 1992), cadaveric human growth hormone injections (used before 1987), corneal transplants from CJD donors, and inadequately decontaminated neurosurgical instruments. These routes of transmission are now prevented by strict regulations: synthetic dura mater, recombinant growth hormone, strict CJD donor exclusion from tissue donation, and specific CJD-safe instrument decontamination protocols. CJD is not transmitted through: casual contact, respiratory exposure, touching, kissing, hugging, sharing food, or blood transfusion in the absence of specific risk factors. Healthcare workers caring for CJD patients who follow standard precautions are not at increased risk. At KIMS, CJD infection control protocols are in place for all procedures involving CJD patients or suspected CJD patients.

Q: We were told my father has "rapidly progressive dementia" but not yet a specific diagnosis. What should we ask for?

Rapidly progressive dementia — dementia developing over weeks to months rather than years — requires an urgent and comprehensive workup to exclude treatable causes before any diagnosis is accepted. The specific investigations you should ensure are requested at KIMS: MRI brain with DWI sequences (for cortical ribboning suggesting CJD, or signal changes suggesting autoimmune or paraneoplastic encephalitis); EEG (for periodic complexes of CJD or epileptic activity); CSF analysis including autoimmune encephalitis antibody panel (anti-NMDAR, LGI1, CASPR2, GABA-B, and others), 14-3-3 protein, RT-QuIC (prion disease test), and standard infectious panel; blood tests including thyroid function, anti-TPO antibody, paraneoplastic antibodies, B12, folate, syphilis, HIV; and CT chest/abdomen/pelvis to look for an occult tumour triggering paraneoplastic encephalitis. If any of these tests identify a treatable cause, treatment should begin immediately. If CJD is confirmed, palliative and symptom management begins. Please call 040-44885000 urgently for a specialist assessment.

Expert MRI DWI imaging for cortical ribboning, EEG for periodic sharp wave complexes, CSF 14-3-3 protein and RT-QuIC testing, comprehensive treatable rapidly-progressive-dementia panel, symptom control, palliative care integration, and genetic counselling for familial CJD at KIMS Neuroscience, Secunderabad, Hyderabad.

View Our Specialists

Prion diseases (transmissible spongiform encephalopathies) are fatal neurodegenerative disorders caused by accumulation of pathologically misfolded prion protein (PrPSc) that templates further misfolding. Creutzfeldt-Jakob disease (CJD) is the most common human prion disease, presenting as a rapidly progressive dementia (weeks to months, not years) with myoclonus, cerebellar ataxia, visual disturbance, and pyramidal/extrapyramidal signs. Four types: sporadic (~85%, no known cause), familial (~10–15%, PRNP gene mutation), iatrogenic (rare, from contaminated surgical instruments or dural grafts), and variant CJD (related to BSE/mad cow disease). Diagnostic pillars at KIMS: MRI DWI showing cortical ribboning and/or basal ganglia hyperintensity (90–95% sensitivity for sCJD); RT-QuIC on CSF (real-time quaking-induced conversion, >99% specificity); EEG showing periodic sharp-wave complexes in late disease; 14-3-3 protein in CSF (supportive). Before accepting CJD: treatable rapidly progressive dementias (autoimmune encephalitis, Hashimoto, paraneoplastic, B12 deficiency, neurosyphilis, CNS lymphoma, heavy metals) must be excluded. No disease-modifying treatment exists, but accurate diagnosis matters: genetic counselling, avoiding harmful interventions (PEG feeding not recommended), end-of-life planning, family understanding, and infection control (prion decontamination protocol).

Rapidly progressive dementia + myoclonus + ataxia: Cognitive decline measured in weeks-to-months (not years) with myoclonus, cerebellar ataxia, visual disturbance, and pyramidal/extrapyramidal signs = CJD until otherwise excluded. Any RPD presentation needs CJD workup at KIMS.
RT-QuIC = >99% specificity: Real-time quaking-induced conversion (RT-QuIC) on CSF detects pathological prion protein with >99% specificity for sporadic CJD. The most specific antemortem test. Sensitivity ~92%. Available at specialised reference centres.
MRI DWI cortical ribboning: High signal on diffusion-weighted imaging (DWI) along the cerebral cortex (cortical ribboning) and/or basal ganglia (caudate, putamen) = highly characteristic of sCJD. 90–95% sensitivity. Pulvinar sign in variant CJD.
Exclude TREATABLE RPDs first: Autoimmune encephalitis (NMDAR, LGI1, CASPR2, GABA-B, AMPAR, DPPX) · Hashimoto encephalopathy · Paraneoplastic · Vitamin B12 deficiency · Neurosyphilis · HIV · Heavy metals · Wernicke · CNS lymphoma · CT/MRI for malignancy. Treatable RPD exclusion panel BEFORE accepting CJD diagnosis.
Heidenhain variant — visual onset: 10–15% of sCJD presents with cortical visual symptoms first (visual hallucinations, cortical blindness, alexia without agraphia, Balint syndrome) before cognitive decline. Often misreferred to ophthalmology. Add CJD to the differential for any unexplained cortical visual loss.
Why diagnosis matters despite no cure: Genetic counselling (familial CJD) · Avoiding harmful interventions (PEG feeding NOT recommended) · End-of-life planning · Family understanding · Public health (decontamination of surgical instruments) · Research participation
Prion decontamination: Standard autoclaving does NOT inactivate prions. Special protocol: 134°C autoclaving for 18+ minutes + 1N NaOH. Single-use surgical instruments where possible. Notify hospital infection control team for any confirmed/suspected CJD patient at KIMS.

Fact	Details
CJD types	Sporadic (~85%, no known cause) · Familial (~10–15%, PRNP gene mutation) · Iatrogenic (rare, from contaminated instruments/grafts) · Variant CJD (BSE-related)
Clinical signature	Rapidly progressive dementia (weeks-months) + myoclonus + cerebellar ataxia + visual disturbance + pyramidal/extrapyramidal signs
MRI	DWI cortical ribboning (90–95% sensitivity for sCJD) · Basal ganglia DWI high signal (caudate, putamen) · Pulvinar sign in variant CJD · Repeat MRI if early imaging negative
RT-QuIC	>99% specificity for prion disease · ~92% sensitivity · CSF test · Most specific antemortem test · Reference laboratory
Other tests	EEG: periodic sharp-wave complexes in late sCJD · 14-3-3 protein in CSF (supportive, less specific than RT-QuIC) · CSF cell count usually normal
Treatable RPD exclusion	Autoimmune antibody panel · Paraneoplastic panel · Thyroid + B12 + folate · VDRL + HIV · Heavy metals · CT chest/abdomen/pelvis for malignancy · MRI brain repeat
Management	No disease-modifying treatment · Symptomatic (clonazepam for myoclonus, levetiracetam for seizures) · Palliative care · PEG feeding NOT recommended (prolongs dying) · Genetic counselling for familial cases

About This Condition

Prion Diseases & CJD at a Glance

The essential facts that shape how prion diseases and CJD are recognised, diagnosed, and managed at KIMS — from the biology of misfolded prion protein, to why diagnosis still matters despite no cure, to the rapidly progressive dementia clinical key that drives the urgent workup.

What it is

Prion diseases (also called transmissible spongiform encephalopathies or TSEs) are a group of fatal neurodegenerative diseases caused by the misfolding of a normal brain protein called the prion protein (PrP) into an abnormal, infectious form (PrPˢᶜ). The misfolded prion protein accumulates in the brain, causing progressive spongiform (sponge-like) degeneration of the cerebral cortex and other brain regions. Creutzfeldt-Jakob Disease (CJD) is the most common human prion disease. All prion diseases are currently incurable and invariably fatal.

Why the diagnosis matters even though CJD is fatal

There are several important reasons to make an accurate CJD diagnosis despite no curative treatment: (1) to distinguish CJD from the many treatable causes of rapidly progressive dementia — autoimmune encephalitis, metabolic encephalopathy, CNS vasculitis, paraneoplastic syndromes — all of which can be cured or significantly improved if identified; (2) to enable appropriate infection control precautions for surgical instruments (prions are not killed by standard sterilisation); (3) to allow families to prepare, make decisions about care, and access palliative services; and (4) for familial CJD, to offer genetic testing and counselling to family members.

How rare is CJD

CJD incidence is approximately 1–2 per million per year globally. In India, with a population of 1.4 billion, this represents approximately 1,400–2,800 cases per year, though this is almost certainly underestimated due to underdiagnosis. The disease occurs in all ethnic groups and all geographic regions. Cases are seen at KIMS from across Telangana and neighbouring states.

Rapidly progressive dementia — the clinical key

The hallmark of CJD is the speed of progression: cognitive decline that reaches severe dementia within weeks to months, not the years typical of Alzheimer's disease. Rapidly progressive dementia (RPD) that reaches disability within 12 months should always prompt a specific investigation for CJD and the other treatable causes of RPD. The workup is urgent.

Appointment

040-44885000

About This Condition

Not All Rapidly Progressive Dementia Is CJD — But CJD Must Be Excluded

A 62-year-old woman in Hyderabad is brought to KIMS by her son. Over the past 10 weeks, she has deteriorated from a fully independent, cognitively intact woman to someone who is disoriented, cannot recognise family members, and has developed involuntary jerking of her limbs (myoclonus) triggered by sudden sounds or touches. She cannot walk steadily. She has been seen by two doctors who said she has dementia and recommended a nursing home.

At KIMS, the 10-week timeline is the critical signal. Alzheimer's disease, Lewy body dementia, and vascular dementia progress over years, not 10 weeks. A cognitive decline producing severe dementia in less than 3 months is rapidly progressive dementia (RPD) and requires a completely different diagnostic approach — one that specifically excludes treatable causes before accepting a fatal diagnosis.

The KIMS RPD workup is initiated immediately. MRI brain with DWI shows the characteristic cortical ribboning pattern: high signal on DWI in a ribbon-like distribution following the cortical surface, particularly in the frontal, parietal, and basal ganglia regions. EEG shows periodic sharp wave complexes (PSWCs). LP is performed: 14-3-3 protein is strongly positive. Autoimmune encephalitis antibody panel is negative. CSF for RT-QuIC (real-time quaking-induced conversion) — the most sensitive and specific test for prion disease — is sent to a reference laboratory.

The clinical picture, MRI, and EEG together are diagnostic of sporadic CJD without awaiting the RT-QuIC result. The RT-QuIC returns positive at 10 days. The diagnosis is confirmed: sporadic Creutzfeldt-Jakob disease.

The family is counselled at KIMS with care and honesty. There is no treatment that will halt or reverse CJD. The goal is now palliative care: symptom management for myoclonus, seizures, and distress; home nursing support; and specialist palliative medicine involvement. She dies 6 weeks later, 16 weeks from the first symptoms. The family is counselled on infection precautions and offered genetic testing to exclude familial CJD.

Book a Consultation

Speak directly with our rapidly progressive dementia specialist team — neurology, neuroradiology, CSF diagnostics, palliative medicine, and clinical genetics coordinated under one roof. Urgent assessment available. No referral required. Monday to Saturday.

040-44885000Emergency: 040-46324365

Understanding the Disease

Types of Prion Disease

Human prion diseases include four principal forms — sporadic, genetic/familial, variant, and iatrogenic CJD — each with distinctive cause, age at onset, and clinical features. The cards below summarise the proportion, cause, and presenting picture of each form.

Sporadic CJD (sCJD)

85–90% of cases — the most common form

•

Cause: Unknown — spontaneous misfolding of normal prion protein.

•

Age at onset: 50–70 years.

•

Clinical features: Rapidly progressive dementia, myoclonus, cerebellar ataxia, visual disturbance.

•

Death in 4–12 months from symptom onset.

Genetic / Familial CJD (gCJD)

10–15% — autosomal dominant inheritance

•

Cause: Inherited PRNP gene mutation (autosomal dominant).

•

Age at onset: Variable; often younger than sCJD.

•

Clinical features: Similar to sCJD; also includes fatal familial insomnia and Gerstmann-Sträussler-Scheinker disease.

•

First-degree relatives can be offered pre-symptomatic genetic testing with counselling.

Variant CJD (vCJD)

<1% globally — BSE-related

•

Cause: Consumption of BSE (mad cow disease) prion-contaminated beef products.

•

Age at onset: Young adults; mean age ~28.

•

Clinical features: Psychiatric features first (depression, anxiety, personality change), then cerebellar ataxia, then dementia.

•

Longer course (mean 14 months). Rare in India given low BSE-contaminated beef exposure.

Iatrogenic CJD (iCJD)

Very rare — medical-procedure transmission

•

Cause: Medical procedures: contaminated surgical instruments, cadaveric dura mater grafts, human growth hormone injections.

•

Age at onset: Variable.

•

Clinical features: Similar to sCJD; cerebellar features prominent when transmitted peripherally (e.g., growth hormone).

•

Now prevented by synthetic dura, recombinant GH, donor exclusion, and CJD-safe instrument protocols.

Recognising Sporadic CJD

Clinical Features of Sporadic CJD

The clinical profile of sporadic CJD spans rapidly progressive dementia (the defining feature), myoclonus (often stimulus-sensitive), cerebellar ataxia, the visual symptoms of the Heidenhain variant, and — particularly in variant CJD — prominent early psychiatric features. Each of these is specifically assessed at KIMS.

Rapidly progressive dementia — the defining feature

Cognitive decline progressing to severe dementia within weeks to months. The speed is what distinguishes CJD from other dementias. Memory loss, disorientation, personality change, and executive dysfunction develop quickly. Language and visuospatial abilities deteriorate. By weeks 8–12 in typical sporadic CJD, most patients cannot recognise family members or communicate meaningfully.

Myoclonus — the involuntary jerks

Sudden, brief, shock-like involuntary muscle contractions occurring in 80–90% of CJD patients. Myoclonus in CJD is often stimulus-sensitive — triggered by sudden noise, touch, or visual stimuli (startle myoclonus). It can be generalised (whole body jerk) or focal (one limb). On EEG, myoclonus correlates with the periodic sharp wave complexes. Myoclonus in this context, combined with rapidly progressive dementia, is highly characteristic of CJD and should prompt specific investigation.

Cerebellar ataxia — prominent in some variants

Unsteadiness of gait, incoordination, and tremor from cerebellar degeneration. Particularly prominent in variant CJD (which begins cerebellar features early) and in some sporadic CJD subtypes. The Heidenhain variant of sCJD presents with rapidly progressive visual disturbance (cortical blindness) as the first feature.

Visual symptoms — the Heidenhain presentation

Approximately 10–15% of sCJD patients present with prominent visual symptoms: blurring, double vision, visual field loss, or hallucinations — from occipital cortex involvement. This is the Heidenhain variant. The visual symptoms typically precede the dementia by several weeks and can lead to incorrect referral to ophthalmology. Normal ophthalmological examination in a patient with rapidly progressive visual loss should prompt MRI brain and CJD investigation.

Psychiatric features — especially in variant CJD

Variant CJD (linked to BSE-contaminated beef) has a distinctive presentation dominated by psychiatric features in the early months: depression, anxiety, social withdrawal, personality change, and sensory symptoms (paraesthesiae). Neurological features (ataxia, myoclonus, dementia) emerge only later. Variant CJD predominantly affects young people (mean age 28) and runs a longer course (mean 14 months). It is rare in India given the low rate of BSE-contaminated beef consumption.

Diagnosis at KIMS

Diagnosis at KIMS — MRI DWI, CSF, RT-QuIC, EEG & Treatable-Cause Exclusion

CJD diagnosis at KIMS combines high-sensitivity MRI DWI imaging, supportive CSF 14-3-3 protein, the highly specific RT-QuIC assay, EEG for periodic sharp wave complexes, and a comprehensive treatable rapidly-progressive-dementia exclusion panel — applied with urgency to every case of rapidly progressive dementia.

MRI brain with DWI — the most sensitive imaging test

MRI brain with DWI (diffusion-weighted imaging) and FLAIR is the single most important investigation for CJD at KIMS. The characteristic pattern: cortical ribboning — high DWI signal following the surface of the cerebral cortex in a ribbon-like pattern, predominantly in the frontal, parietal, and occipital cortex. Basal ganglia high signal on DWI/FLAIR (particularly putamen and caudate) is characteristic. Thalamic pulvinar sign on FLAIR (high signal in the posterior thalamus, "pulvinar sign") is specific for variant CJD. Sensitivity of MRI DWI for sCJD is approximately 90–95% — the highest of all CJD diagnostic tests. A normal MRI does not exclude CJD in early disease.

CSF 14-3-3 protein

The 14-3-3 protein is a neuronal protein released into CSF during rapid neuronal death. Elevated CSF 14-3-3 is a supportive marker for CJD — sensitivity approximately 85–90%, but specificity is limited (also elevated in stroke, encephalitis, and other rapidly destructive brain conditions). At KIMS, CSF 14-3-3 is sent as part of the RPD panel but is interpreted in the clinical context, not as a standalone test. CSF S100B protein and total tau are additional markers sent simultaneously.

RT-QuIC — the most specific test

Real-time quaking-induced conversion (RT-QuIC) is a novel CSF test that detects misfolded prion protein by seeding an amplification reaction. Sensitivity approximately 87–96%, specificity greater than 99% for CJD. RT-QuIC on nasal brushings (olfactory epithelium) has even higher sensitivity. At KIMS, CSF RT-QuIC is sent to a national reference laboratory when CJD is suspected. A positive RT-QuIC with compatible clinical features and MRI is confirmatory of prion disease without requiring brain biopsy.

EEG — characteristic periodic complexes in sCJD

The EEG in sporadic CJD typically shows periodic sharp wave complexes (PSWCs) or generalized periodic discharges occurring at approximately 1–2 Hz — one complex roughly every 1–2 seconds, often triphasic or sharp in morphology. This pattern is present in approximately 60–70% of sCJD cases, usually appearing in the middle to late stages of illness. PSWCs are not specific to CJD but their presence in a patient with RPD and myoclonus is strongly suggestive. Variant CJD does not typically show PSWCs.

Excluding treatable RPD — the most important workup step

Before diagnosing CJD, a comprehensive treatable RPD panel is sent at KIMS: full autoimmune encephalitis antibody panel (anti-NMDAR, LGI1, CASPR2, GABA-B, AMPAR, and others); paraneoplastic antibodies (anti-Hu, anti-Yo, anti-Ri, anti-CV2, anti-DPPX); thyroid function and anti-TPO antibody (Hashimoto encephalopathy); vitamin B12, folate; syphilis serology; HIV; heavy metal screen; CT chest/abdomen/pelvis for occult malignancy. Any positive result for a treatable cause changes the entire management approach and must be acted upon.

Treatment

Management at KIMS — Supportive and Palliative Care

There is currently no disease-modifying treatment for any human prion disease. Several drugs have been tested in clinical trials (quinacrine, pentosan polysulphate, doxycycline, flupirtine) without demonstrable benefit. At KIMS, management is therefore focused on symptom control, palliative care integration, infection control, and genetic counselling for familial CJD.

Symptom Control

Comfort-focused, symptom-targeted prescribing

Myoclonus: Clonazepam 0.5–2mg at night or twice daily is the most effective agent for CJD myoclonus. Levetiracetam 500–1,500mg twice daily is an alternative. Valproate 500–750mg twice daily is used when myoclonus is severe and persistent.

Seizures: Managed per standard epilepsy protocol. Levetiracetam or valproate first-line.

Anxiety and agitation: Low-dose lorazepam or midazolam SC infusion in the late stages, titrated to comfort. Haloperidol for psychotic features if present.

Sleep disturbance: Melatonin, low-dose benzodiazepines. Fatal familial insomnia (FFI) — a rare prion disease producing complete insomnia — is managed with sedation.

Pain: Paracetamol and opioids (morphine SC) as needed in late stages for any pain or distress. Comfort-focused prescribing.

Palliative Care Integration

Specialist palliative medicine from the point of diagnosis

KIMS integrates specialist palliative medicine from the point of CJD diagnosis. Given the rapid course of sporadic CJD (median survival 4–6 months from symptom onset), early palliative care involvement is not premature — it is essential.

Goals of care discussions with the family: whether to pursue PEG tube feeding (controversial in CJD, usually not recommended as it prolongs the dying process without quality of life benefit), preferred place of care and death, and advance care planning. Home nursing support, hospice care coordination, and caregiver support are arranged by KIMS.

Infection Control Precautions

Prion-specific decontamination protocols at KIMS

Prions are resistant to standard sterilisation methods (autoclaving at 121°C, formalin, alcohol, ultraviolet light). Surgical instruments used in a patient with known or suspected CJD at KIMS are managed with specific protocols: (1) single-use instruments wherever possible; (2) reusable instruments are incinerated or treated with sodium hypochlorite or sodium hydroxide (1M NaOH, 1 hour) plus prolonged autoclaving at 134°C.

All KIMS clinical staff follow standard precautions for CJD patients — prion disease is not transmitted through casual contact, blood, or respiratory secretions in the healthcare setting.

Genetic Counselling — For Familial CJD

PRNP gene testing and pre-symptomatic counselling

Approximately 10–15% of CJD is genetic (gCJD), caused by autosomal dominant mutations in the PRNP gene. If genetic CJD is suspected (positive family history, young age at onset, or specific clinical features of GSS or FFI), PRNP gene sequencing is arranged at KIMS through a reference genetics laboratory.

First-degree relatives of patients with confirmed genetic prion disease can be offered pre-symptomatic genetic testing with genetic counselling. Predictive testing for a fatal, untreatable condition requires careful consideration — KIMS arranges specialist genetic counselling before any predictive testing.

Related Conditions

Prion diseases and CJD belong to the family of infectious and post-infectious neurological disorders evaluated and managed at KIMS Neuroscience:

Neurocysticercosis Lyme Disease (Neurological)Neuroinfectious Disorders & Complications (Master)

FAQs

Frequently Asked Questions

There is currently no treatment that can halt or reverse CJD. This is one of the most difficult things to communicate, and we do so at KIMS with the care it deserves. However, the most important first step is to confirm that the diagnosis is actually CJD — because several conditions that can look exactly like CJD in the early weeks are treatable and can be reversed. These include autoimmune encephalitis (particularly anti-NMDAR, anti-LGI1, and other antibody-mediated encephalitides), Hashimoto encephalopathy, paraneoplastic encephalopathy from an occult cancer, and severe metabolic disturbance. At KIMS, a comprehensive workup specifically tests for all these treatable causes before CJD is accepted as the diagnosis. If CJD is confirmed, the focus shifts entirely to keeping your mother comfortable, managing symptoms like the jerking movements and distress, and supporting your family through this. Please call 040-44885000.

Brain biopsy is not the standard diagnostic approach for CJD and is rarely performed. The diagnosis is made at KIMS through a combination of: MRI brain — specifically the DWI sequence showing the characteristic cortical ribboning pattern (high signal along the brain surface), which is present in approximately 90–95% of sporadic CJD; EEG — showing periodic sharp wave complexes in approximately 60–70% of cases; CSF analysis including 14-3-3 protein and RT-QuIC (the most specific test for prion disease). Together, these investigations provide a confident clinical diagnosis in most cases without biopsy. Brain biopsy is reserved for atypical cases where other diagnoses (treatable ones) have not been excluded and tissue diagnosis is essential for management decisions. Please call 040-44885000.

The answer depends on the type of CJD your brother had. Sporadic CJD (the most common form, approximately 85% of cases) is not inherited and does not run in families. If your brother had sporadic CJD, your personal risk is no higher than the general population (approximately 1–2 per million per year). Variant CJD is not directly transmitted between family members — it comes from a dietary exposure (BSE-contaminated beef), not from your brother. Familial (genetic) CJD is autosomal dominant — if your brother had a PRNP gene mutation, each first-degree relative has a 50% chance of inheriting the mutation. If your brother's CJD was genetic, KIMS can arrange PRNP gene testing for you with full genetic counselling before and after the result. This is an important conversation that deserves specialist support. Please call 040-44885000.

Iatrogenic CJD (from medical procedures) is documented but extremely rare, and has been associated with specific historical procedures now discontinued: cadaveric dura mater grafts (used in neurosurgery before 1992), cadaveric human growth hormone injections (used before 1987), corneal transplants from CJD donors, and inadequately decontaminated neurosurgical instruments. These routes of transmission are now prevented by strict regulations: synthetic dura mater, recombinant growth hormone, strict CJD donor exclusion from tissue donation, and specific CJD-safe instrument decontamination protocols. CJD is not transmitted through: casual contact, respiratory exposure, touching, kissing, hugging, sharing food, or blood transfusion in the absence of specific risk factors. Healthcare workers caring for CJD patients who follow standard precautions are not at increased risk. At KIMS, CJD infection control protocols are in place for all procedures involving CJD patients or suspected CJD patients.

Rapidly progressive dementia — dementia developing over weeks to months rather than years — requires an urgent and comprehensive workup to exclude treatable causes before any diagnosis is accepted. The specific investigations you should ensure are requested at KIMS: MRI brain with DWI sequences (for cortical ribboning suggesting CJD, or signal changes suggesting autoimmune or paraneoplastic encephalitis); EEG (for periodic complexes of CJD or epileptic activity); CSF analysis including autoimmune encephalitis antibody panel (anti-NMDAR, LGI1, CASPR2, GABA-B, and others), 14-3-3 protein, RT-QuIC (prion disease test), and standard infectious panel; blood tests including thyroid function, anti-TPO antibody, paraneoplastic antibodies, B12, folate, syphilis, HIV; and CT chest/abdomen/pelvis to look for an occult tumour triggering paraneoplastic encephalitis. If any of these tests identify a treatable cause, treatment should begin immediately. If CJD is confirmed, palliative and symptom management begins. Please call 040-44885000 urgently for a specialist assessment.

Weeks, not years — that is the speed that distinguishes CJD from other dementias, and it is the speed that makes diagnosis urgent. Not because CJD is treatable, but because several conditions that look exactly like it in the first weeks are completely treatable.

At KIMS Neuroscience, Secunderabad, Hyderabad, rapidly progressive dementia receives a full specialist workup: MRI DWI, EEG, CSF RT-QuIC and 14-3-3, and a complete treatable-cause exclusion panel. When CJD is confirmed, palliative care and family support begin immediately. Call 040-44885000 for an RPD assessment. Emergency (new severe neurological symptoms): 040-46324365.

040-44885000

International enquiries: info@kimsneurosciences.com